Azapirones for attention deficit hyperactivity disorder: A systematic review
- Forfatter(e)
- Matsui, Y. Matsunaga, A. Matsuda, Y. Kishi, T. Iwata, N.
- År
- 2016
- Tidsskrift
- Pharmacopsychiatry
- Sider
- 97-106
- Kategori(er)
- ADHD
- Tiltakstype(r)
- Antidepressiva
- Abstract
Introduction: No meta-analysis has evaluated azapirones (serotonin1A receptor partial agonists) as anxiolytics for attention deficit hyperactivity disorder (ADHD).
Methods: Randomized controlled trials (RCTs) and single-arm trials published before October 27, 2015 were retrieved from major healthcare databases and clinical trial registries. Relative risk and 95% confidence intervals were calculated.
Results: 5 RCTs (n = 429) and 3 single-arm studies (n = 70) were identified. 3 RCTs compared buspirone vs. methylphenidate in children/adolescents, one buspirone patches vs. placebo patches in children/adolescents, and one atomoxetine plus buspirone vs. atomoxetine vs. placebo in adults. The single-arm studies were buspirone trails in children/adolescents. All-cause discontinuation rates and adverse events did not differ between pooled buspirone and methylphenidate groups. No other meta-analyses of buspirone efficacy and safety vs. comparators were conducted due to insufficient data. 2 RCTs found no significant differences in parent and teacher ADHD-Rating Scale total scores between buspirone and methylphenidate, while one reported that methylphenidate improved parent and teacher ADHD-RS total scores vs. buspirone.
Discussion: It remains unclear whether buspirone use has benefit for ADHD patients and therefore further evidence is needed for better clinical use of buspirone in patients with ADHD:
(PsycINFO Database Record (c) 2016 APA, all rights reserved)